'You could feel it in your veins, like how cold it was': Using paint and selfies to cope with chemo
After being diagnosed with Stage III breast cancer when she was just 24, Lauren Sylliboy said the enormity of her illness didn't hit her right away. But exactly 14 days after her first chemotherapy treatment, that changed. Her hair started falling out and Sylliboy said she looked in the mirror and realized her illness was showing.
Do results of gene-expression profiles change whether patients with ER-positive breast cancer receive adjuvant chemotherapy?Journal of Clinical Oncology
Patients with ER-negative, but not ER-positive, isolated locoregional recurrence after unilateral breast cancer derive significant benefit from chemotherapy.
Authors: Pan T, Mao T, Yang H, Wang H, Wang Y Abstract The present study was designed to explore the sensitivity of MDA-MB-231 cells to cisplatin after silencing the expression of TG-interacting factor (TGIF) protein. Cell viability was measured using an MTT assay. Cell apoptosis was detected by the annexin V and dead cell assay and the Hoechst staining assay. Protein expression was analyzed using western blot analysis. A colony formation assay was also performed. It was observed that cisplatin reduced the expression of TGIF protein in a dose- and time-dependent manner. Silencing TGIF significantly suppressed the c...
Conclusion: Providing patients with strategies to further control nausea (p.r.n. antiemetics) in addition to guideline-consistent antiemetics is recommended for practice. Because the nausea experience contributes to symptom incidence in the next phase and cycle and because the nausea intensity demonstrated a significant relationship with function and global health/QOL, proactive supportive approaches are strongly recommended. Implications for Practice: Delayed nausea control may be improved by adhering to guideline-consistent antiemetics and using p.r.n. antiemetics. Delayed nausea control would contribute to patients...
ConclusionAlthough the study was terminated owing to the altered liver function, it showed that there was a trend to greater shrinkage of tumor in the combination group for ER-positive, HER2-negative postmenopausal breast cancer.
ConclusionThese findings reveal for the first time that hydroxytyrosol is an active partner in combined therapies with paclitaxel against breast cancer. Combination with hydroxytyrosol would also ensure a less oxidative impact of chemotherapeutic drugs that could potentially improve patient wellness.
ConclusionThe presence of microcalcifications on imaging and DCIS on initial CNB are associated with residual disease after neoadjuvant chemotherapy in TNBC. These variables can aid in identifying patients with TNBC suitable for inclusion in trials evaluating non‐surgical management after neoadjuvant chemotherapy.
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent adverse reaction caused by chemotherapeutic agents, especially the taxanes. CIPN can persist from months to years after completion of chemotherapy, decreasing quality of life for cancer survivors. The aim of this study was to explore the incidence and risk factors of persistent CIPN among women with breast cancer receiving neoadjuvant chemotherapy.
The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.
This article presents a snapshot of my experience of being a nurse who became a service user with breast cancer. It begins by outlining the Humanization of Healthcare Framework ( Todres et al, 2009 ), which is a values-based context that can be used to underpin daily care. Generic applications for each of the dimensions of the framework are suggested. This framework is then used to contextualise my experience of receiving my diagnosis and the ensuing chemotherapy. Using examples from my personal narrative, I make some recommendations for 'small actions' that can contribute to more humanised and person-centred care. I also ...